Incyte Corp. (INCY) exhibits 92.8% gross margins and 42.4% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 12.5x enterprise multiple and 6.9% implied options volatility.
Sustained 92.8% gross profitability converts into 29.5% operating margin and 42.4% ROIC, outpacing sector cost of capital.
ROIC: 42.4% // GM: 92.8%YoY revenue trajectory of +21.2% paired with 4.99% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +21.2% // FCF YLD: 4.99%Altman Z-Score of 10.04 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 10.04 // F-SCORE: 9/9Trading at 18.4x trailing P/E (15.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 18.4x // EV/EBITDA: 12.5xOptions market prices a ±6.9% implied move with a 0.72 put/call ratio around $114.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.72Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend 25.0% net margins.
NET MARGIN: 25.0% // D/E: 0.15x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for INCY & activate live FRED threshold breach alerts.